Regenerative treatment using a radioelectric asymmetric conveyor as a novel tool in antiaging medicine: an in vitro beta-galactosidase study

Salvatore Rinaldi,1,2 Margherita Maioli,1,3,4 Sara Santaniello,3,4 Alessandro Castagna,1,2 Gianfranco Pigliaru,3,4 Sara Gualini,3,4 Matteo Lotti Margotti,5 Arturo Carta,6 Vania Fontani,1,2 Carlo Ventura1,4,71Department of Regenerative Medicine, Rinaldi Fontani Institute, Florence; 2Department of Neu...

Full description

Bibliographic Details
Main Authors: Rinaldi S, Maioli M, Santaniello S, Castagna A, Pigliaru GF, Gualini S, Margotti ML, Carta A, Fontani V, Ventura C
Format: Article
Language:English
Published: Dove Medical Press 2012-06-01
Series:Clinical Interventions in Aging
Subjects:
Online Access:https://www.dovepress.com/regenerative-treatment-using-a-radioelectric-asymmetric-conveyor-as-a--peer-reviewed-article-CIA
Description
Summary:Salvatore Rinaldi,1,2 Margherita Maioli,1,3,4 Sara Santaniello,3,4 Alessandro Castagna,1,2 Gianfranco Pigliaru,3,4 Sara Gualini,3,4 Matteo Lotti Margotti,5 Arturo Carta,6 Vania Fontani,1,2 Carlo Ventura1,4,71Department of Regenerative Medicine, Rinaldi Fontani Institute, Florence; 2Department of Neuro Psycho Physio Pathology and Neuro Psycho Physical Optimization, Rinaldi Fontani Institute, Florence; 3Department of Biomedical Sciences, University of Sassari, Sassari; 4Laboratory of Molecular Biology and Stem Cell Engineering, National Institute of Biostructures and Biosystems, Bologna; 5Department of Information Technology and Statistical Analysis, Rinaldi Fontani Institute, Florence; 6Ophthalmology Section, University of Parma, Parma; 7Cardiovascular Department, S Orsola Malpighi Hospital, University of Bologna, Bologna, ItalyBackground: Beta-galactosidase is the most widely used biomarker for highlighting the processes of cellular aging, including neurodegeneration. On this basis, we decided to test in vitro whether a set of rescuing/reparative events previously observed by us in subjects treated with radioelectric asymmetric conveyor (REAC) technology may also involve antagonism of a marker of aging-related degenerative processes, as assessed by a reduction in beta-galactosidase at the cellular level.Methods: Human adipose-derived stem cells were cultured at different passages, ranging from 5 to 20, with or without REAC exposure for 12 hours. The cells were then processed for biochemical beta-galactosidase staining and morphological microscopy analysis.Results: We observed a significant reduction in expression of senescence associated-beta-galactosidase, and a persistence of fibroblast-like morphology typical of human adipose-derived stem cells, even at late passages.Conclusion: Our results indicate the ability of REAC technology to counteract in vitro senescence of human adipose-derived stem cells, and prompt the hypothesis that such technology may be exploited to antagonize in vivo senescence of tissue-resident or transplanted stem cells playing an important role in clinical treatment of age-related processes.Keywords: aging, adipose-derived stem cells, neurodegenerative diseases
ISSN:1178-1998